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Abstract
Background: The putative tumor suppressor WWOX gene spans the common chromosomal fragile site 16D
(FRA16D) at chromosome area 16q23.3-24.1. This region is a frequent target for loss of heterozygosity and
chromosomal rearrangement in ovarian, breast, hepatocellular, prostate carcinomas and other neoplasias. The
goal of these studies was to evaluate WWOX protein expression levels in ovarian carcinomas to determine if
they correlated with clinico-pathological parameters, thus providing additional support for WWOX functioning
as a tumor suppressor.
Methods:  We performed WWOX protein expression analyses by means of immunobloting and
immunohistochemistry on normal ovaries and specific human ovarian carcinoma Tissue Microarrays (n = 444).
Univariate analysis of clinical-pathological parameters based on WWOX staining was determined by χ 2 test with
Yates' correction. The basic significance level was fixed at p < 0.05.
Results: Immunoblotting analysis from normal ovarian samples demonstrated consistently strong WWOX
expression while 37% ovarian carcinomas showed reduced or undetectable WWOX protein expression levels.
The immunohistochemistry of normal human ovarian tissue sections confirmed strong WWOX expression in
ovarian surface epithelial cells and in epithelial inclusion cysts within the cortex. Out of 444 ovarian carcinoma
samples analyzed 30% of tumors showed lack of or barely detectable WWOX expression. The remaining ovarian
carcinomas (70%) stained moderately to strongly positive for this protein. The two histotypes showing significant
loss of WWOX expression were of the Mucinous (70%) and Clear Cell (42%) types. Reduced WWOX
expression demonstrated a significant association with clinical Stage IV (FIGO) (p = 0.007), negative Progesterone
Receptor (PR) status (p = 0.008) and shorter overall survival (p = 0.03).
Conclusion: These data indicate that WWOX protein expression is highly variable among ovarian carcinoma
histotypes. It was also observed that subsets of ovarian tumors demonstrated loss of WWOX expression and is
potentially associated with patient outcome.
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Background
The WWOX  gene, originally cloned by our laboratory,
spans a genomic region greater than 1 Mb in size and is
the second most common chromosomal fragile site,
FRA16D (16q23) [1,2]. Abnormalities affecting WWOX at
the genomic and expression level have been reported in
numerous neoplasias and cancer derived cell lines includ-
ing, breast, ovarian, esophageal, lung, stomach, liver, pan-
creas and hematological malignancies [3-12]. We
observed that ectopic WWOX expression inhibited
anchorage independent growth and in vivo tumorigenicity
of highly aggressive breast carcinoma lines, suggesting a
putative tumor suppressor role for this novel protein
[13,2].
WWOX encodes a 46 KD, 414-amino acid protein that
contains two WW domains at the NH2 terminus and a
short chain oxidoreductase (SDR) central domain [1]. The
first WW domain- is involved in protein-protein interac-
tions by binding the specific proline rich motif PPXY and
several potential candidate partner proteins have been
postulated [14,15]. Within the SDR domain, the presence
of WWOX amino acid residues, serine 281, and 293-
YNRSK-297 make up a catalytic signature motif conserved
in short-chain steroid dehydrogenases [16]. We originally
reported high WWOX mRNA expression levels in ovary,
prostate, testis and breast [1]. In this study we analyzed
WWOX protein expression pattern in normal ovary and
ovarian carcinomas. We correlated WWOX protein expres-
sion with ovarian carcinoma histotypes and clinico-path-
ological parameters. In addition, since we recently
observed a strong association between loss of WWOX
expression and estrogen and progesterone receptor (ER
and PR) status in breast cancer [12], we also investigated
any potential association between expression of sex ster-
oid hormone receptors and WWOX in ovarian cancer.
Methods
Western blot analysis
Total protein extracts were prepared from snap frozen tis-
sue of 38 human ovarian carcinomas and 5 normal
human ovarian tissues. As negative control for WWOX
protein expression we used protein extracts from the ovar-
ian cell line PEO1 that does not express WWOX due to a
homozygous deletion affecting exons 4–8 of this gene [4],
a kind gift of Dr. Hani Gabra at Imperial College London,
UK. As positive control we used the same cell line stably
transfected with a WWOX expressing vector (PE01-
WWOX) [10,12]. Total cell protein lysates were made
using RIPA buffer (50 mM Tris pH7.5, 150 mM NaCl,
0.5% sodium deoxycholate, 1% Triton X-100, 0.1% SDS)
containing protease inhibitor cocktail (Roche, Man-
nheim, Germany). For western blotting 50 ug of total pro-
tein was separated by 12.5% SDS-PAGE and transferred to
PVDF membranes (Millipore, Billerica, MA). Immunode-
tection was performed using Protein Detector™ (KPL,
Gaithersburg, MD) western blotting reagents as described
by the manufacturer. WWOX protein was detected using
affinity-purified anti-WWOX rabbit polyclonal primary
antibodies developed in our laboratory (final concentra-
tion 280 ng/ml) [12] and HRP conjugated anti-rabbit sec-
ondary antibody (KPL, city, state, 1:2000 dilution)
followed by chemiluminescence autoradiography. Actin
was used as the protein loading control and it was
detected using monoclonal anti-actin antibody (ICN bio-
medicals, Burlingame, CA, 1:1000 dilution) and HRP
conjugated anti-mouse secondary antibody (KPL,
1:5000). Quantitation of X-ray films exposed to western
blot chemiluminescence-emitting membranes was per-
formed using a Kodak digital science Image Station
440CF. Protein loading and signal intensity was control-
led by normalizing each sample to the aforementioned
positive control, PE01-WWOX as previously described
[10,12].
Ovarian tissue microarrays
The MD Anderson Cancer Center ovarian TMA was pre-
pared by D.R. at the J.L laboratory [17] with samples from
441 patients with primary epithelial ovarian cancer that
had undergone surgery at M. D. Anderson Cancer Center
between 1990 and 2001. Follow-up information was
updated through June 2003. Histopathologic diagnoses
assigned at the time of treatment were based on World
Health Organization criteria, each sample was reclassified
by grade based on the Gynecologic Oncology Group
(GOG) criteria [18] and each case was also classified by
disease stage according to the International Federation of
Gynecology and Obstetrics (FIGO) system [19]. The
appropriate institutional committee approved use of
human tissue blocks and clinical records reviews. Each
core was scored individually and the results are reported
as the mean of at least two replicate core sample measure-
ments [20].
We also used a second ovarian TMA set generated at the
Fox Chase Cancer Center (FCCC) tumor bank by R.P. at
the A.J.P.K laboratory. This TMA set included a total of 86
ovarian tumors and 21 normal ovarian samples. Cores of
normal ovaries were used as positive controls. Only pri-
mary mucinous carcinomas of the ovary where included
on this cohort of patients. Selection criteria was based on
histopathological diagnosis made by a trained pathologist
on whole sections, histochemical stainings, immuhohis-
tochemical staining, and clinical assessment of the
patient. By pooling the TMA sets from both institutions
we were able to successfully analyze in duplicate WWOX
protein staining from a total of 444 invasive surface epi-
thelial derived primary ovarian carcinomas that included
Serous (n = 375), Endometroid (n = 40), Mucinous (n =
10) and Clear Cell Carcinoma (CCC) (n = 19) histologicalBMC Cancer 2005, 5:64 http://www.biomedcentral.com/1471-2407/5/64
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subtypes. A subset of these cases (n = 323) was success-
fully processed and analyzed for allowing comparative
analysis of WWOX protein expression with ER and PR
status.
Immunostaining method
Anti-WWOX immunostaining was performed as previ-
ously reported [12]. Mouse monoclonal antibodies for
ER, NCL-ER-6F11 (Novocastra, UK) and PR, NCL-PGR-
312 (Novocastra, UK) were used according to manufac-
turer recommendations. The anti-PR antibody used in
these studies is able to recognize only the A isoform of this
receptor [21].
Evaluation of immunohistochemical staining
Staining intensity was measured using a Chromavision
Automated Cellular Imaging System (Chromavision®
ACIS®, San Juan Capistrano, CA) as previously described
[12].
The methods for scoring cytoplasmic or nuclear staining
are based on different program functions of the ACIS® and
are the recommended by the manufacture. For anti-
WWOX staining measurements we employed the generic
DAB software application provided by ACIS. The area of
each individual TMA core was considered for the measure-
ments in its totality. The software determines brown
intensity (i.e. positive stained cells) regardless of the area
covered by the positive cells. The cutoff to differentiate
positive and negative staining was determined to be a
mean intensity of 63 (arbitrary staining intensity units,
s.i.u.) over a total of 255 (color saturation scale). There-
fore, cores with values = 63 s.i.u were 'negative' for WWOX
immunostaining, i.e. no brown staining observable. Val-
ues between 63 and = 65 s.i.u. were considered to be in the
'weak/low' staining category, i.e. barely visible brown
staining, 65 to 81 s.i.u were considered 'moderate' and
cores with staining intensity values > 81 s.i.u were consid-
ered to fall in the 'strong' staining category. For sake of
simplicity cases were classified in two groups: a) negative
+ low = Negative-Low WWOX group, i.e. any core with a
value = 65 in staining intensity and b) moderate + strong
= High WWOX group, i.e. any core with values above 65
in staining intensity. The Negative/Low WWOX group was
composed of 79% (105/133) completely negative cases
and 21% (28/133) weak cases. The mean WWOX inten-
sity staining for normal ovarian surface epithelium (OSE)
fell in the moderate category (mean value 70 ± 4).
Anti-ER and PR antibodies
For performing anti-ER and anti-PR determinations we
utilized the nuclear antigen software application provided
by ACIS. Only areas of tumor in each TMA core were con-
sidered for measurements. The free form drawing tool
provided by the software was used to select tumoral areas
and to exclude other structures. A final score was deter-
mined by the percentage of brown stained nuclei (i.e. pos-
itive cells) over the total of tumor cell nuclei measured
(i.e. positive plus negative cells). Only cores with at least
10% tumor were included in the analysis. For the receptor
analyses, positivity of nuclear staining was defined as fol-
lows: weak > 5% stained nuclei, moderate 5–40% stained
nuclei and strong >50% stained nuclei.
Statistical methods
Univariate analysis of clinical-pathological parameters
based on WWOX staining was determined by χ 2 test with
Yates' correction. The basic significance level was fixed at
p < 0.05 and all data was analyzed using SPSS statistical
software (Version 11.0; SPSS Inc., Chicago, IL).
Results
Western blot analysis
Immunoblotting analysis demonstrated that full length
WWOX protein was the predominant WWOX isoform
expressed in both normal ovary and ovarian carcinomas
(Figure 1B). The anti-WWOX antibody used was raised
against the WW domains [2] and should detect all poten-
tial WWOX isoforms. The specificity of this WWOX anti-
body in the immunoblotting analyses was demonstrated
by observing no immunoreactive products in cell extracts
from the PEO1 ovarian carcinoma cell line used as nega-
tive control (Figure 1A). In addition, as a positive control
PEO1 cells were stably transfected with a WWOX expres-
sion vector (Figure 1A).
Normal ovarian tissues displayed a consistently strong
WWOX specific signal while WWOX protein expression
levels were extremely variable among tumor samples.
Some tumors displayed barely detectable, if any, WWOX
protein when compared to normal tissue, e.g. T108 while
other samples had significantly higher WWOX levels e.g.
T578 in Figure 1. We concluded that 26% (10/38) of
tumors over-expressed WWOX, 34% (13/38) expressed
normal WWOX levels and 40% (15/38) of tumors had
levels lower than 50% that observed in normal ovary.
Pattern of WWOX staining in normal ovary
Initially we characterized the cellular localization of
WWOX protein expression in normal ovaries by IHC
using the antibody described in the previous section. The
specificity of the WWOX antibody for IHC analysis was
validated by observing that the immunoreactivity was
abolished by pre-absortion to the recombinant GST-
WWOX fusion protein used to raise the antibody (data
not shown).
The analysis of TMA cores and whole sections of normal
human ovary showed that WWOX protein is constitu-
tively expressed at high levels in normal OSE cells (FigureBMC Cancer 2005, 5:64 http://www.biomedcentral.com/1471-2407/5/64
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2A), in epithelial inclusion cysts within the cortex (Figure
2B) and in scattered granulosa-lutein cells surrounding
aged corpora lutea or corpora albicans (not shown). Pos-
itive staining was also detected in one observed Walthard
nest within the ovarian hilus and in a few stromal cell
patches likely related with hormone production. In all
cases the inmunostaining had a homogeneous and diffuse
pattern that was localized to the cytoplasm.
WWOX staining in ovarian carcinomas
WWOX expression was highly variable among ovarian
tumors (n = 444). WWOX staining intensity was deter-
mined in all four major surface epithelium derived ovar-
ian carcinoma histotypes, i.e. Serous, Endometroid,
Mucinous and Clear Cell (Table 1).
Thirty percent of ovarian carcinomas (133/444) showed
loss of WWOX protein expression while 70% (311/444)
demonstrated positive staining including cases with very
strong staining (Figure 3A–I) (Table 1). Among serous car-
cinomas, 29% of the cases (109/375) fell in the negative/
low group and 71% (266/375) stained moderately or
strongly positive. The most typical WWOX staining pat-
tern observed for all histotypes was cytoplasmic and dif-
fuse, no tissues demonstrated any nuclear staining.
Interestingly, some of the carcinomas showed a distinctive
WWOX protein expression in normal ovary and ovarian adenocarcinomas as determined by immunoblot analysis Figure 1
WWOX protein expression in normal ovary and ovarian adenocarcinomas as determined by immunoblot analysis. A) Total 
protein extracts from PEO1 cell lines transfected with an empty vector or a WWOX expressing vector were analyzed by 
immunobloting with the anti-WWOX antibody. Note: no immunoreactive bands are observed in the vector transfected cell 
line. B) WWOX protein expression was determined by immunoblotting of total protein extracts from 38 ovarian carcinoma 
samples. Five normal ovarian tissue extracts are shown on the first five lanes. Quantitation of WWOX protein expression. 
Autoradiographs of WWOX and actin were digitized using the Kodak digital science Image Station 440CF. WWOX expres-
sion in each sample was normalizated to actin to correct for loading differences. In turn these numbers obtained from each 
tumor were normalized and expressed as relative to the normal ovarian values (i.e. Relative Expression).BMC Cancer 2005, 5:64 http://www.biomedcentral.com/1471-2407/5/64
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strong cell membrane staining pattern (Figure 3). Other
tumors displayed a predominantly apical border staining,
in conjunction with staining of what appeared to be lumi-
nal secretions (Figure 3B). Among endometroid carcino-
mas 23% of the cases (9/40) were negative/low and 77%
(31/40) stained moderately or strongly positive for
WWOX expression. This histological subtype showed a
diffuse and apical cytoplasmic pattern of protein expres-
sion (Figure 3D, E). Among the CCC group, 42% of the
cases (8/19) were negative/weak while 58% (11/19)
stained moderately or strongly for WWOX (Figure 3G–I).
Within the mucinous carcinoma group, we observed that
most tumors (7 out of 10 cases) did not stain for WWOX
expression. Furthermore the three positive mucinous car-
cinomas were clearly below the mean value for normal
OSE. The immunoreactivity localized to the cytoplasm as
in the other histotypes but in a very specific perinuclear
fashion (Figure 3J). The high rate of absence of WWOX
protein expression among the mucinous carcinoma group
was statistically different compared to the other three his-
totypes (p = 0.0131, Table 1).
WWOX staining analysis according to stage and grade
WWOX expression was next correlated with tumor Stages
(FIGO). We observed that 23% of Stage I (7/31), 29% of
Stage II (8/28), 31% of Stage III (74/242) and 48% of
Stage IV (31/65) tumors showed negative/low WWOX
WWOX immunohistochemical staining of normal ovary Figure 2
WWOX immunohistochemical staining of normal ovary. A) Representative photomicrograph (20X) of normal ovary displaying 
positive staining in ovarian surface epithelial cells. B) Photomicrograph (20X) showing strong WWOX inmunostaining localiz-
ing to the cytoplasm of inclusion cyst epithelial cells.
Table 1: WWOX intensity staining according to the four major epithelial derived ovarian carcinoma histotypes.
Histology WWOX intensity Total
Low (Negative/Weak) High (Moderate/Strong)
Serous carcinoma 109/375 (29%) 266/375 (71%) 375
Endometroid carcinoma 9/40 (23%) 31/40 (77%) 40
Clear cell carcinoma 8/19 (42%) 11/19 (58%) 19
Mucinous carcinoma * 7/10 (70%) 3/10 (30%) 10
Total 133/444 (30%) 311/444 (70%) 444
* (χ 2 = 8.67; p = 0.0131)BMC Cancer 2005, 5:64 http://www.biomedcentral.com/1471-2407/5/64
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WWOX inmunohistochemical staining in ovarian carcinoma samples by histotypes Figure 3
WWOX inmunohistochemical staining in ovarian carcinoma samples by histotypes. A-C. Serous ovarian carcinomas. A, Strong-
Moderate. Note heterogeneity in staining intensity pattern in this tumor sample; B, Moderate. Note predominance of apical 
staining in this papillary serous ovarian carcinoma; C Weak-Negative, WWOX lack of staining observed in approximately 30% 
of serous carcinoma cases. D-F. Endometroid ovarian carcinomas. D and E positive WWOX cytoplasmic staining and F negative 
staining. G-I. Clear Cell ovarian Carcinomas. G, representative photomicrograph of one of a moderately WWOX positive CCC 
case, while H and I, represent typical negative cases. J-L. Mucinous ovarian carcinomas, J, representative mildly positive case and 
K representative mucinous carcinoma of the endocervicoid subtype with demonstrating no WWOX staining. L, mucinous car-
cinoma of the intestinal subtype also negative for WWOX staining.BMC Cancer 2005, 5:64 http://www.biomedcentral.com/1471-2407/5/64
Page 7 of 10
(page number not for citation purposes)
protein expression. We detected a statistically significant
trend between the decrease in WWOX expression and
more advanced FIGO stages (-b = -0.135; p trend= 0.007,
Table 2). No correlation was found between tumor grade
(GOG) and WWOX staining (p = 0.707, Table 2).
WWOX staining analysis according to relapse and survival
An analysis of WWOX protein expression relative to dis-
ease relapse was performed in a subset of cases from the
MDACC TMA (n = 354). Between relapsing and non-
relapsing cases no statistical difference was observed
regarding WWOX expression (p = 0.094) (Table 2).
Among cases with progressive disease, 46% (27/59)
showed negative/low WWOX levels of expression while
54% (32/59) fell in the positive category. It was possible
to evaluate survival in cases from the MDACC group as
shown by the Kaplan-Meier plot (Figure 4). Importantly,
we observed a statistically significant correlation of
WWOX expressing cases with longer overall survival and
loss of WWOX protein expression correlated with shorter
overall survival (p = 0.03).
WWOX staining analysis in correlation with ER and PR 
status
We analyzed the association of WWOX with ERα  and PR
status in ovarian carcinoma cases (n = 323). When ER sta-
tus was correlated with WWOX expression levels no sig-
nificant differences were found (Table 2). On the other
hand, a statistically significant correlation was observed
Table 2: Clinical parameters and steroid receptor status analyzed in correlation with WWOX staining.
Clinical parameters WWOX intensity Total p value
Low (Negative/Weak) High (Moderate/Strong)
Grade (GOG)
1 4 (23%) 13 (77%) 17 p = 0.707
2 9 (33%) 18 (67%) 27
3 107 (33%) 215 (67%) 322
Stage (FIGO)
I 7 (23%) 24 (77%) 31 p = 0.007
II 8 (29%) 20 (71%) 28
III 74 (31%) 168 (69%) 242
IV 31(48%) 34 (52%) 65
Relapse
No 31(32%) 66 (68%) 97 p = 0.09
Yes 61(31%) 137(69%) 198
Progressive disease 27(46%) 32 (54%) 59
ER
Negative 22 (25%) 66 (75%) 88 p = 0.984
Positive 59 (25%) 176 (75%) 235
PR
Negative 70 (29%) 170 (71%) 240 p = 0.00
Positive 12 (14%) 71 (86%) 83
Kaplan Meier Plot analysis showing the pattern of Overall  Survival relative to WWOX protein expression Figure 4
Kaplan Meier Plot analysis showing the pattern of Overall 
Survival relative to WWOX protein expression.BMC Cancer 2005, 5:64 http://www.biomedcentral.com/1471-2407/5/64
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between WWOX expression and PR expression (p = 0.008,
Table 2). In the WWOX negative cases 85% (70/82) were
PR negative while only 15% (12/83) were PR positive.
Discussion
Since our original cloning of WWOX [1] abundant evi-
dence has accumulated indicating that this gene likely
plays a role in either tumor initiation or progression in
various neoplasias including ovarian cancer [3-12].
WWOX spans the second most common chromosomal
fragile site, FRA16D. This genomic region is prone to chro-
mosome breakage, recombination and gross
rearrangements. Multiple ovarian carcinoma studies have
demonstrated high frequency of allelic losses for specific
chromosomal regions on 16q [22] and since the losses
have been found both in low and high-grade tumors it has
been proposed to be an early event in ovarian carcinoma
development [23]. Loss of heterozygosity at 16q23.2-
q24.2 has been correlated with ovarian carcinoma metas-
tasis and advanced tumor stages [24]. Comparative
Genomic Hybridization (CGH) studies confirmed those
observations also indicating high frequency of 16q21-q24
genomic losses in advanced invasive ovarian carcinoma
stages [25,26]. Taken together the data indicates that a
gene, likely WWOX, located at 16q23-24 is associated
with a worse prognosis in ovarian cancer.
In this study WWOX protein expression in normal ovary
was predominantly observed in the OSE and epithelial
inclusions, both sites proposed to be where ovarian epi-
thelial neoplastic transformation originates. Because of
this finding together with the observations of Paige
(2001) [4], that ovarian carcinoma cell lines have high fre-
quency of genomic losses affecting the WWOX  gene
including homozygous deletions, we considered it of rel-
evance to analyze WWOX protein expression among the
four major surface epithelial derived ovarian carcinoma
histotypes. Our analysis by immunoblotting and IHC
demonstrated that about one third of ovarian carcinomas
displayed extremely reduced or absent WWOX protein
expression.
It is worth noting that in all instances, normal and tumor,
WWOX staining was exclusively cytoplasmic and in some
serous carcinomas staining was also localized to the apical
cell membrane or luminal border. This is similar to our
observations in breast tumors [12], where WWOX was
always cytoplasmic without nuclear staining. This is also
in agreement with observations from other groups [11].
This is in stark contrast with Watanabe (2003) [27] who
observed that some cells of normal and tumor breast and
gastric cases had WWOX protein expression localized to
the nuclei. Possibly this discrepancy is due to the use of
different antibodies.
In this ovarian cancer study, we also observed that Serous
and Endometroid histotypes express normal or high
WWOX but two rare but well described ovarian carcinoma
histotypes, mucinous and clear cell (28,29,30), demon-
strated a higher frequency of loss of WWOX protein
expression. This association was more significant for the
mucinous type, for which we observed that 70% (7/10) of
cases were devoid of WWOX protein expression.
Eventhough a small number of mucinous cases were stud-
ied the overall high frequency of decreased or loss of
WWOX in these tumors as a group is intriguing. Border-
line significance was found for the pure CCC for which
42% of cases demonstrated no or very low WWOX protein
expression (Figure 3H versus 3G).
Primary mucinous ovarian tumors have been shown to
carry a higher frequency of K-ras mutations as one of the
few genetic hallmarks able to distinguish it from other his-
totypes, while CCC are characterized by a lack of p53
mutations. Mucinous carcinomas and CCC, has been
associated with a higher frequency of resistance to chem-
otherapy (31). Interestingly, in our study, we observed a
statistically significant trend between loss of WWOX
expression and worse patient outcome. Patients whose
tumors expressed WWOX at moderate or high levels fared
better than those with low expression of this enzyme (Fig-
ure 4). We also found a statistically significant correlation
with loss of WWOX and stage IV at initial diagnosis
(FIGO). The association with overall survival could be
due to an increased frequency of loss in higher stage
tumors that are associated with a poorer outcome or alter-
natively due, in part, to an increased frequency of clear cell
and mucinous tumors which have a lower likehood of
responding to therapy [31]. It was also of interest that we
observed a positive correlation between WWOX and PR
expression. In contrast to our previous observations in
breast cancer in which we observed a strong correlation
between ER and PR with WWOX expression [12], in this
ovarian study, only PR was associated with WWOX
expression (Table 2). Specifically PR negative ovarian car-
cinomas also lacked WWOX expression. Progestins acting
through the PR have been postulated to be protective for
ovarian carcinoma development [32,33] due to a postu-
lated ability of inhibiting cell proliferation and inducing
apoptosis (34,35). We noticed that all (100%) of our ana-
lyzed mucinous carcinomas were PR negative which
agrees with the literature regarding absence of PR expres-
sion in mucinous tumors [36,37] while 90% of CCC were
PR negative. These correlations raise the question of
whether the observed positive association between PR
loss and WWOX loss is a consequence of the predomi-
nance of WWOX loss in the two aforementioned histo-
types, rather than a direct mechanistic association
between WWOX and PR. Changes in progesterone signal-
ing and regulation of progesterone-responsive genes canBMC Cancer 2005, 5:64 http://www.biomedcentral.com/1471-2407/5/64
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be of critical significance in the ovarian tumorigenic proc-
ess by itself [38]. The opposite could be true as well i.e.
that high levels of WWOX expression is associated with PR
expression and as a consequence related to the putative
protective effect of progestins that in turn could be associ-
ated with more favorable patient outcomes.
Conclusion
We provide evidence that WWOX protein expression is
frequently altered and highly variable in ovarian carcino-
mas. The loss of WWOX expression shows association
with Mucinous and CCC histotypes more than the others
and also shows a tendency with PR negative expression.
Significantly, reduced WWOX protein expression corre-
lates with less favorable outcome.
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